Peptide · Fact sheet
Pemvidutide
Also known as ALT-801
Pemvidutide is not FDA approved. Phase 2 studies report reductions in liver fat, MASH activity, and body weight, but confirmatory evidence, fibrosis benefit, long-term safety, and major clinical outcomes remain unresolved.
What is Pemvidutide?
Pemvidutide is a manufactured peptide designed to activate GLP-1 and glucagon receptors.
It is being developed primarily for metabolic liver disease and obesity, with trial endpoints spanning imaging, biopsy, biomarkers, and weight.
Benefits people look for
Its glucagon activity is intended to add liver-fat and energy-expenditure effects to GLP-1 biology.
Positive mid-stage results are scientifically meaningful but remain less mature than a successful confirmatory program or regulatory approval.
What the evidence supports
- A randomized MASLD study reported lower liver fat and body weight than placebo.
- The IMPACT Phase 2b study reported MASH-resolution signals, while a clear confirmatory fibrosis benefit remains a central question.
All research areas
- MASH and MASLD
- Liver fat
- Obesity
- Fibrosis and cardiometabolic markers
- MASH with fibrosis
- Chronic weight management
- Metabolic liver disease
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- Gastrointestinal adverse effects are common across this drug class and appeared in pemvidutide trials.
- Trial discontinuations and sponsor-selected analyses can affect apparent efficacy.
- Uncommon and long-term harms are not yet characterized as they are for approved medicines.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Early human evidenceRandomized Phase 2 studies support biological and clinical signals, including liver-fat and biopsy outcomes. Larger confirmatory trials and longer safety follow-up are still needed.
Selected research to read
Controlled trial of liver-fat, inflammatory, and body-weight outcomes.
Biopsy-based MASH and fibrosis study with short primary follow-up.
Official Phase 2b trial design, status, population, and endpoints.
FDA approval & research status
Pemvidutide remains investigational in the United States. Its MASH and obesity programs have not produced an FDA-approved product.
No FDA-approved use is documented in the records summarized on this page.
Mid-stage MASH and metabolic research
Pemvidutide has Phase 2 evidence and a completed Phase 2b MASH program, but confirmatory development and regulatory review remain unresolved.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Whether MASH improvements are confirmed in Phase 3
- Whether fibrosis and liver-related clinical outcomes improve
- Long-term cardiovascular and safety outcomes
- How its benefit-risk profile compares directly with other incretin and glucagon co-agonists
The takeaway
Pemvidutide has credible mid-stage liver and weight data, but it is still a Phase 2 research program rather than an established MASH or obesity medicine.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1pubmedRandomized pemvidutide MASLD study
Controlled trial of liver-fat, inflammatory, and body-weight outcomes.
- 2
- 3clinical trialsClinicalTrials.gov: IMPACT
Official Phase 2b trial design, status, population, and endpoints.